Jordi Bruix is Professor of Medicine at the University of Barcelona and Director of the Barcelona Clinic Liver Cancer (BCLC) Group within the Liver Unit at the Hospital Clinic of Barcelona, Spain. Prof. Bruix has been the principal investigator of studies and clinical trials that have changed practice in the field of hepatocellular carcinoma (HCC),  including  development  of  diagnostic criteria and prognostic models and establishment of chemoembolization, SORAFENIB and REGORAFENIB as EFFECTIVE therapy. He founded the International Liver Cancer Association (ILCA) and was its president from 2006 to 2009.
Read more.

Data Protection and Privacy Policy

EASL International Liver Foundation

We take the protection of your personal data seriously, meaning that we process your personal data with due care and in accordance with applicable data protection laws.

Consent

Please note that by clicking the box “I agree”, you explicitly agree to the processing of your personal data for the purposes and pursuant to the terms and conditions mentioned in our Data Protection and Privacy Policy available at here“.

Contact

For any question or request, please contact us at EASL International Live Foundation, Rue Daubin 7, 1203 Geneva, Switzerland, telephone 0041 (0)22 552 2497 gdpr@easl-ilf.org